Distribution partnership agreement between MVision AI and Tecnosan

Finland, Helsinki, December 14, 2022 – MVision AI, the leading provider of AI-powered Guideline Based Segmentation solution for Radiotherapy planning and Tecnosan, advanced healthcare technology for radiotherapy and medical physics supplier in Italy announced cooperation and signing of a new Distribution partnership agreement. Both companies will closely cooperate on current and future projects to innovate medical solutions and services to improve outcomes for patients and healthcare providers all over Italy by providing high-quality, innovative, patient-centric radiotherapy solutions.

The cooperation between MVision AI and Tecnosan got off to a bright start thanks to the joint participation in the AIRO (Italian Association of Radiotherapy and Clinical Oncology) Congress, that took place at the end of November in Bologna and registered a record of attendance, with more than 950 attendees.

“MVision AI is delighted to partner with Tecnosan to bring guideline-compliant AI segmentation for Italian patients, as Italy is very important market for MVision and Radiation therapy in Italy has a long tradition, with Italians being early adopters of this new technology already from 1901. Also we appreciate Tecnosan’s over 30 years of experience and strong expertise in the field of healthcare and look forward to introducing reliable and high-quality AI segmentation solutions for cancer patients undergoing radiotherapy,” says Mahmudul Hasan, CEO and founder of MVision AI.

In Italy most hospitals are public and both – small Radiotherapy units, with just 1/2 linacs, and large departments with a higher number of linacs and special machines could benefit from this AI technology, that is not only based on experts’ consensus but originates from reliable and regularly updated guidelines.

“In Tecnosan, we work with people for people and we aim to support the doctors in their battle against cancer. Having an effective tool that helps in daily and time-demanding tasks, such as segmentation and contouring, which MVision AI brilliantly does, makes a difference in daily workflow and saves time. And time is probably the most precious resource in a RT department,” says Mattia Dell’Orsola, CEO of Tecnosan.

For more information, please contact:

Mahmudul Hasan, MVision AI
+358 40 5489 229
info@mvision.ai

Mattia Dell’Orsola, Tecnosan
+39 0461982681
radioterapia@tecnosan.it

 

About MVision AI

MVision AI is a pioneering, cloud-based software service provider for radiotherapy treatment planning. Company’s AI-powered automatic segmentation tool helps to standardize contouring and automate segmentation to streamline radiotherapy treatment planning workflow. MVision AI is headquartered in Helsinki, Finland, with a global network of more than 50+ employees and official distributors in Denmark, France, Greece, Italy, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, UK and Ireland, North America, Canada, Australia and New Zealand. Get in touch: www.mvision.ai | LinkedIn: MVision AI.

 

About Tecnosan

Tecnosan is an Italian company that chooses the most innovative and patient-centric solutions worldwide and operates as a distributor in Italy, taking care of the whole process from pre-sales to maintenance and building a network of local users. Tecnosan was founded in 1985 and has entirely focused on Radiation Oncology and Medical Physics for RT since 2011. From the beginning SGRT technology has been the core of Tecnosan business, successfully counting 65+ installations in Italy, and over the last years Tecnosan management has decided to enlarge its portfolio in order to provide a full set of solutions to RT departments. Tecnosan – Medtech with a human touch. Get in touch: https://tecnosan.it | LinkedIn: Tecnosan.

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

29.5.2024

Refining Volumes – a Study on Cardiac Substructures’ Impact on Survival in Lung Cancer Patients Treated with Radiation Therapy

Cardiac diseases and cancers are leading causes of death [1]. Many cancer patients have preexistent cardiac impairment or have risk factors of developing it. On the other hand, survival after being diagnosed with cancer is increasing, so relatively more patients may develop long-term side effects. Cardiac diseases and cancers are…

Articles

24.5.2024

Personalised AI radiotherapy ROIs at your fingertips

MVision's configuration solution (ConfigUI) introduces advanced region of interest (ROI) operations and smart post-processing options to support multiple clinical scenarios and complex treatment planning workflows. MVision Contour+ offers an impressive number of structures (more than 270), based on organs or anatomically defined regions, such as lymph node levels. However, we…

Articles

21.5.2024

Time Optimisation in Radiation Therapy Planning: Insights from UK Surveys

Recently published data give a glimpse on the time spent for treatment preparation in UK radiation oncology centres. As expected,organ-at-risk and target contouring contouring is the most time-consuming step of the process. However, multiple factors influence the amplitude of this interval, and these new findings can be used as further…

Articles